Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?

Linz U, Ulus B, Neuloh G, Clusmann H, Oertel M, Nolte K, Weis J, Heussen N, Gilsbach JM.

Anticancer Drugs. 2014 Apr;25(4):375-84. doi: 10.1097/CAD.0000000000000062.

PMID:
24423983
2.

Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.

Weller M, Müller B, Koch R, Bamberg M, Krauseneck P; Neuro-Oncology Working Group of the German Cancer Society.

J Clin Oncol. 2003 Sep 1;21(17):3276-84.

PMID:
12947063
3.

Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors.

Ono A, Kanno H, Hayashi A, Nishimura S, Kyuma Y, Sato H, Ito S, Shimizu N, Chang CC, Gondo G, Yamamoto I, Sasaki T, Tanaka M.

Int J Clin Oncol. 2007 Apr;12(2):125-30. Epub 2007 Apr 27.

PMID:
17443280
4.

Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.

Wang Y, Chen X, Zhang Z, Li S, Chen B, Wu C, Wang L, Zhang X, Wang J, Chen L, Jiang T.

Neurosurg Rev. 2014 Jan;37(1):73-8. doi: 10.1007/s10143-013-0490-x. Epub 2013 Aug 3.

PMID:
23912878
5.

Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.

Rieger L, Rieger J, Winter S, Streffer J, Esser P, Dichgans J, Meyermann R, Weller M.

Acta Neuropathol. 2000 May;99(5):555-62.

PMID:
10805101
6.

The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.

Nikkhah G, Tonn JC, Hoffmann O, Kraemer HP, Darling JL, Schachenmayr W, Schönmayr R.

J Neurooncol. 1992 May;13(1):13-24.

PMID:
1613536
7.
8.

Characterization and chemosensitivity of two cell lines derived from human glioblastomas.

Izumu I, Mineura K, Watanabe K, Kowada M.

J Neurooncol. 1993 Aug;17(2):111-21.

PMID:
8145054
9.

Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.

Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D, Kouvaris J.

Molecules. 2009 Apr 16;14(4):1561-77. doi: 10.3390/molecules14041561. Review.

10.

Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.

Tanaka S, Kamitani H, Amin MR, Watanabe T, Oka H, Fujii K, Nagashima T, Hori T.

J Neurooncol. 2000;46(2):157-71.

PMID:
10894369
11.

[Chemotherapy for malignant gliomas: an update].

Wakabayashi T, Natsume A, Fujii M.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1283-7. Japanese.

PMID:
24105052
12.

Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay.

Jordan JP, Hand CM, Markowitz RS, Black P.

J Neurooncol. 1992 Sep;14(1):19-35.

PMID:
1335043
13.

Chemosensitivity testing in malignant melanoma.

Ugurel S, Tilgen W, Reinhold U.

Recent Results Cancer Res. 2003;161:81-92.

PMID:
12528801
14.

Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC).

Recht LD, Glantz MJ, Meitner P, Glantz L, Akerley W, Wahlberg L, Saris S, Cole BF.

J Neurooncol. 1998 Feb;36(3):201-8.

PMID:
9524098
15.

The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.

Pyrko P, Schönthal AH, Hofman FM, Chen TC, Lee AS.

Cancer Res. 2007 Oct 15;67(20):9809-16.

16.

Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.

Leweke F, Damian MS, Schindler C, Schachenmayr W.

Pathol Res Pract. 1998;194(3):149-55.

PMID:
9587932
17.

[Evaluation of ACNU alone and combined with tegafur as additions to radiotherapy of the treatment of malignant gliomas--a cooperative clinical trial].

Ushio Y, Abe H, Suzuki J, Tanaka R, Kitamura K, Miwa T, Matsutani M, Takeuchi K, Takakura K, Nomura K, et al.

No To Shinkei. 1985 Oct;37(10):999-1006. Japanese.

PMID:
3000412
18.

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.

Bock HC, Puchner MJ, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A.

Neurosurg Rev. 2010 Oct;33(4):441-9. doi: 10.1007/s10143-010-0280-7. Epub 2010 Aug 13.

19.

In vitro chemosensitivity test of human brain tumors using a three-dimensional organ culture with a collagen gel matrix.

Yuki K, Uozumi T, Kodama Y, Kurisu K, Mikami T.

J Neurooncol. 1994;21(3):225-32.

PMID:
7699417
20.

Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma.

Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U.

Oncology. 2009;76(3):184-9. doi: 10.1159/000201943. Epub 2009 Feb 13.

PMID:
19218824
Items per page

Supplemental Content

Write to the Help Desk